Lack of NAPRT expression in some tumors, such as neuroblastoma or glioblastoma [17], and lymphomas [22], places NAPRT as a biomarker for the use of NA as a chemoprotectant agent in the treatment with NAMPT inhibitors [19]. This evidence concerns the gene NAPRT and neuroblastoma.